CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $1.44B, above the global median of $520.53M
- PositionP/E ratio is 15.59×, lower than 95% of its Medical Devices peers (median 35.3×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.81%Below 5Y avg (1.62%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
62.5%Moderate
Last Ex-Dividend
Jul 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.50BCNY1.11B · vs all stocks (USD)
Trailing P/E
15.59xvs Medical Devices peers
Revenue (TTM)
9.68BCNY1.44B · vs all stocks (USD)
Profit Margin
5.06%vs Medical Devices peers
Beta
0.1170xvs all stocks
52-Week Change
-28.68%vs all stocks
Market Capitalization
7.50BCNY1.11B · vs all stocks (USD)
Enterprise Value
5.88BCNY872.31M · vs all stocks (USD)
Trailing P/E
15.59xvs Medical Devices peers
Forward P/E
7.56xvs Medical Devices peers
Price to Sales (TTM)
0.7813xvs Medical Devices peers
Price to Book (MRQ)
0.9725xvs Medical Devices peers
Enterprise to Revenue
0.6070xvs Medical Devices peers
Enterprise to EBITDA
7.36xvs Medical Devices peers
Gross Margin
24.64%vs Medical Devices peers
Profit Margin
5.06%vs Medical Devices peers
Operating Margin
8.20%vs Medical Devices peers
Return on Assets (TTM)
2.42%vs Medical Devices peers
Return on Equity (TTM)
6.04%vs Medical Devices peers
Revenue (TTM)
9.68BCNY1.44B · vs all stocks (USD)
Revenue per Share (TTM)
15.83CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-2.30%vs Medical Devices peers
Gross Profit (TTM)
2.38BCNY352.76M · vs all stocks (USD)
EBITDA (TTM)
833.88MCNY123.66M · vs all stocks (USD)
Net Income (TTM)
489.94MCNY72.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-22.70%vs Medical Devices peers
Operating Cash Flow (TTM)
931.92MCNY138.20M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
588.24MCNY87.24M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.81%vs all stocks
5-Year Average Dividend Yield
1.62%vs all stocks
Payout Ratio
62.50%vs Medical Devices peers
Minority Interest (Equity)
323.15MCNYFY2025 · Dec 31, 2025Revenue
9.74BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
7.29BCNYFY2025 · Dec 31, 2025Gross Profit
2.45BCNYFY2025 · Dec 31, 2025Operating Income
703.86MCNY104.38M · vs all stocks (USD)
Pre-tax Income
591.12MCNYFY2025 · Dec 31, 2025Income Tax Expense
62.99MCNYFY2025 · Dec 31, 2025Net Income
528.13MCNYFY2025 · Dec 31, 2025EBIT
632.53MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
990.57MCNYFY2025 · Dec 31, 2025Research & Development
442.03MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
409.54MCNYFY2025 · Dec 31, 2025Other Operating Expenses
74.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
18.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
41.41MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.8700CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.8700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
604.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
604.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
528.13MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.80MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.02BCNYFY2025 · Dec 31, 2025Free Cash Flow
638.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.97BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
528.13MCNYFY2025 · Dec 31, 2025Other Non-cash Items
83.26MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
16.37MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
391.35MCNYFY2025 · Dec 31, 2025Capital Expenditures
-380.51MCNYFY2025 · Dec 31, 2025Net Acquisitions
103.56MCNYFY2025 · Dec 31, 2025Purchase of Investments
-23.94MCNYFY2025 · Dec 31, 2025Sale of Investments
118.04MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-182.85MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.19BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.15BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-342.62MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.27MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-309.99MCNYFY2025 · Dec 31, 2025Shares Outstanding
606.64MSharesUpdated Aug 19, 2026Float Shares
398.39MSharesUpdated Aug 19, 2026% Held by Insiders
38.03%vs all stocks
% Held by Institutions
5.21%vs all stocks
Total Cash (MRQ)
3.11BCNY461.33M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.13CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.16BCNY172.29M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1434xvs Medical Devices peers
Current Ratio (MRQ)
1.41xvs Medical Devices peers
Book Value per Share (MRQ)
12.82CNYUpdated Aug 19, 2026Total Assets
14.82BCNY2.20B · vs all stocks (USD)
Total Current Assets
8.89BCNYFY2025 · Dec 31, 2025Total Liabilities
6.86BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.93BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
314.89MCNYFY2025 · Dec 31, 2025Total Current Liabilities
6.55BCNYFY2025 · Dec 31, 2025Cash
2.97BCNYFY2025 · Dec 31, 2025Cash Equivalents
128.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.09BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.91BCNYFY2025 · Dec 31, 2025Inventory
2.90BCNYFY2025 · Dec 31, 2025Accounts Payable
2.53BCNYFY2025 · Dec 31, 2025Short-term Debt
1.05BCNYFY2025 · Dec 31, 2025Other Current Liabilities
355.53MCNYFY2025 · Dec 31, 2025Long-term Debt
139.39MCNYFY2025 · Dec 31, 2025Common Stock (Book)
606.68MCNYFY2025 · Dec 31, 2025Retained Earnings
4.11BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.96BCNY1.18B · vs all stocks (USD)
Treasury Stock
17.74MCNYFY2025 · Dec 31, 202552-Week Low
11.40CNYUpdated Aug 19, 202652-Week High
17.44CNYUpdated Aug 19, 202652-Week Change
-28.68%vs all stocks
Beta
0.1170xvs all stocks
50-Day MA
12.53CNYUpdated Aug 19, 2026200-Day MA
14.21CNYUpdated Aug 19, 2026Avg 10-Day Volume
7.22MSharesUpdated Aug 19, 2026Avg 30-Day Volume
8.20MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.8000CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 15.59×, lower than 95% of its Medical Devices peers (median 35.3×)Notable
P/E ratio: 15.59Industry median: 35.30Industry P5: 16.46Peers compared: 59.00
Price-to-book is 0.97×, lower than 95% of its Medical Devices peers (median 3.08×)Notable
Price-to-book: 0.97Industry median: 3.08Industry P5: 1.04Peers compared: 59.00
Financial Health
Altman Z-Score 2.03: grey zoneSignificant
Altman Z-Score: 2.03
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $1.44B, above the global median of $520.53MNotable
Revenue (USD): 1,435,912,562.278Global Median: 520,528,949.311
Levered free cash flow is $87.24M, above the global median of $16.24MNotable
Levered free cash flow (USD): 87,236,162.842Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Medy-Tox Inc.
1 interpretationClose Below 40W SMA With Profitability
Aptiv PLC
1 interpretationClose Below 40W SMA With Profitability
Embecta Corp.
1 interpretationClose Below 40W SMA With Profitability